Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed supratentorial glioblastoma multiforme (with areas of necrosis) by surgical biopsy or excision within 4 weeks of study~* Tumor and/or any associated edema limited to one hemisphere and unifocal~* No gross invasion of a ventricular surface~* Tumor accessible~* No other astrocytoma~* No multifocal or recurrent malignant glioma~* No disease below the tentorium or beyond the cranial vault~PATIENT CHARACTERISTICS:~Age:~* Adult~Performance status:~* Zubrod 0-1~Life expectancy:~* At least 8 weeks~Hematopoietic:~* Hemoglobin at least 10 g/dL (transfusion allowed)~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.0 mg/dL~* Serum glutamic-oxaloacetic transaminase (SGOT) or Serum glutamic-pyruvic transaminase (SGPT) no greater than 2 times normal~Renal:~* Blood Urea Nitrogen (BUN) no greater than 25 mg/dL~* Creatinine no greater than 1.5 mg/dL~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No hypersensitive or idiosyncratic reaction to bleomycin~* No other prior malignancies within the past 2 years except nonmelanomatous skin cancer or carcinoma in situ of the cervix or urinary bladder~* No other major medical illness or psychiatric impairment that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy for glioblastoma multiforme~* No prior radiosensitizer for glioblastoma multiforme~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy to the head or neck resulting in overlapping radiotherapy fields~Surgery:~* See Disease Characteristics~* Recovered from prior surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiation therapy followed by bleomycin via Ommaya reservoir (Type: EXPERIMENTAL): 60.0 Gy/30 fractions x 2.0 Gy. Then within 2-6 weeks after completion of radiation therapy or at the time a patient experiences disease progression during or immediately after completion of radiation therapy, if clinically feasible, a modified Ommaya reservoir is implanted with the delivery catheter in the tumor or tumor cyst/cavity. Bleomycin, 15 units per week, is then given via the Ommaya reservoir without interruption for a maximum of two years as long as there is no toxicity above grade 3 or evidence of disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).